-
Jan 17, 2025 | 
healio.com | Rob Volansky |Shenaz Bagha |Vibeke Strand |John R.P. Tesser
You've successfully added Rheumatoid Arthritis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
-
Mar 27, 2024 | 
acrjournals.onlinelibrary.wiley.com | Vibeke Strand |Laure Gossec |Laura Coates
Supporting Information Filename Description acr25333-sup-0001-Disclosureform.pdfPDF document, 1.5 MB Disclosure Form acr25333-sup-0002-TableS1.docxWord 2007 document , 34.1 KB Supplemental Table S1. Spearman correlations at baseline and at Week 16 between PsAID-12 scores and comparative health outcomes.
-
Feb 10, 2024 | 
healio.com | Rob Volansky |Shenaz Bagha |Vibeke Strand |Eric Roberts
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A lot can change in a year. But has it? The first Humira biosimilar hit the U.S. market a little over a year ago.
-
Nov 17, 2023 | 
hcplive.com | Nehad Soloman |Andrew Sharobeem |Vibeke Strand
0:00 Introduction 01:29 Precision Medicine in Rheumatoid Arthritis (RA) 03:34 Biomarkers and Diagnostic Tools in RA 07:08 Science Behind Molecular Signature Response Classifier (MSRC) Test 08:30 Accelerate Information of Molecular Signatures (AIMS) Study 10:33 Experience with MSRC Test in Clinical Practice 12:46 Heterogeneity of RA and Development of Other Biomarkers in RA 14:49 MSRC Test Coverage by Medicare and Future of Precision Medicine in RA 17:54 Safe Step Act in RA Management and...
-
Nov 10, 2023 | 
ard.bmj.com | Roy Fleischmann |Vibeke Strand |Tatsuya Atsumi |Iain B McInnes
AbstractObjectives To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis. Methods Two phase 3, double-blind randomised controlled trials including patients with inadequate responses to methotrexate (contRAst 1) or conventional synthetic/biologic disease-modifying antirheumatic drugs (cs/bDMARDs; contRAst 2).
-
Sep 12, 2023 | 
ard.bmj.com | Roy Fleischmann |Vibeke Strand |Tatsuya Atsumi |Iain B McInnes
In contRAst 1, otilimab 90 mg resulted in a significantly greater proportion of patients achieving CDAI LDA at week 12 vs placebo, but otilimab 150 mg did not (20.9% (p=0.0188) and 19.8% (p=0.0368) vs 13.9%). In contRAst 2, both doses resulted in a significant difference versus placebo (26.5% and 25.1%, respectively, vs 11.4%, p<0.0001 for both) (figure 2, table 2, online supplemental figure 3).
-
Mar 7, 2023 | 
hcplive.com | Vibeke Strand
Vibeke Strand, MD, MACR, FACP: If you find you’ve got a patient who’s a nonresponder to a TNF [tumor necrosis factor inhibitor], it can be difficult to prescribe another therapy. A good example of this is the JAK inhibitors. where our US FDA has required that a patient fail a TNF before they receive a JAK inhibitor. That’s not a great idea.
-
Mar 7, 2023 | 
hcplive.com | Vibeke Strand
Vibeke Strand, MD, MACR, FACP: The AIMS study, which is named Accelerate Information of Molecular Signatures, was to essentially develop a clinical database of longitudinal data from patients with RA [rheumatoid arthritis] treated by providers in real-world settings. In other words, in clinical practice, with the idea of looking at what happens when the MSRC [molecular signature response classifier] test is utilized or not utilized.
-
Mar 7, 2023 | 
hcplive.com | Vibeke Strand
I don’t think we have a lot of tools to tell us how to treat and what therapy. We know there’s the R4RA trial where synovial biopsies were performed, and RNA [ribonucleic acid] sequence-based identification showed that patients with low or absent B-cell lineage gene expression signature in their synovial tissue were significantly correlated with a better response with tocilizumab than rituximab. That makes a lot of sense, but we don’t have any more data from the R4RA for any other therapies.
-
Feb 28, 2023 | 
hcplive.com | Vibeke Strand
Vibeke Strand, MD, MACR, FACP: The TNF [tumor necrosis factor] inhibitors are a fantastic class of therapy in rheumatoid arthritis [RA], and our first effective biologic therapy. We now have 5 of them, which is a nice thing. However, usually only 1 or 2 are included in the formulary. Although they behave similarly, there may be some reason that a certain patient or physician would like to use one vs another. That may be a bit problematic, but that’s not a major problem.
